4.575
Precedente Chiudi:
$4.46
Aprire:
$4.38
Volume 24 ore:
14,208
Relative Volume:
0.30
Capitalizzazione di mercato:
$217.50M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.00%
1M Prestazione:
+11.04%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Capsovision Inc Stock (CV) Company Profile
Nome
Capsovision Inc
Settore
Industria
Telefono
(408) 370-4790
Indirizzo
18805 COX AVENUE SUITE 250, SARATOGA
Confronta CV con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CV
Capsovision Inc
|
4.65 | 208.61M | 0 | 0 | 0 | 0.00 |
![]()
ABT
Abbott Laboratories
|
132.35 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
![]()
BSX
Boston Scientific Corp
|
95.71 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
![]()
SYK
Stryker Corp
|
369.65 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
![]()
MDT
Medtronic Plc
|
95.99 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
![]()
EW
Edwards Lifesciences Corp
|
73.27 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-28 | Iniziato | Roth Capital | Buy |
2025-07-28 | Iniziato | The Benchmark Company | Speculative Buy |
Capsovision Inc Borsa (CV) Ultime notizie
CapsoVision's (CV) Sell (E-) Rating Reiterated at Weiss Ratings - MarketBeat
Analyzing Vyome (NASDAQ:HIND) and CapsoVision (NASDAQ:CV) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Short Interest in CapsoVision, Inc. (NASDAQ:CV) Rises By 430.0% - MarketBeat
CapsoVision announces senior leadership transition in clinical operations By Investing.com - Investing.com Nigeria
CapsoVision announces senior leadership transition in clinical operations - Investing.com India
CapsoVision Announces Leadership Transition Plans - TipRanks
CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - The Manila Times
AI-Enabled Capsule Endoscopy Leader CapsoVision to Present at ROTH Healthcare Conference in NYC - Stock Titan
CapsoVision (NASDAQ:CV) Stock Price Down 2.2%Should You Sell? - MarketBeat
Financial Analysis: Longevity Health (NASDAQ:XAGE) versus CapsoVision (NASDAQ:CV) - Defense World
CapsoVision CFO Kevin Lundquist Steps Down - TipRanks
CapsoVision chief financial officer steps down; company begins search for successor - Investing.com Australia
CapsoVision CFO Kevin Lundquist Resigns - MarketWatch
Capsovision says Kevin Lundquist steps down as CFOSEC filing - MarketScreener
Ingestible Sensors Market Set for Dynamic Growth with Key Players CapsoVision, Inc., BodyCAP, etectRx - openPR.com
Head to Head Comparison: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Smart Pills Market Worth US$1.30 Billion By 2030 With 11.2% CAGR - Barchart.com
Smart Pills Market worth US$1.30 billion by 2030 with 11.2% CAGR - openPR.com
FY2028 EPS Estimates for CapsoVision Lowered by Roth Capital - MarketBeat
Critical Analysis: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Insider Transactions Reported | CapsoVision(CV)saw insider trading activity on 8/22/2025 - AInvest
FY2028 EPS Estimates for CapsoVision Cut by Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Issues Earnings Results - MarketBeat
CapsoVision 2025 Q2 Earnings Net Loss Narrows 12.2% - AInvest
CapsoVision Reports Second Quarter 2025 Financial Results - GlobeNewswire
CapsoVision Reports Revenue Growth and IPO Success - TipRanks
CapsoVision Revenue Jumps 17 Percent - AOL.com
Smart Pills Company Evaluation Report 2025 | Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies - Yahoo Finance
CapsoVision (NASDAQ:CV) versus ReShape Lifesciences (OTCMKTS:RSLSD) Head to Head Comparison - Defense World
Reviewing ReShape Lifesciences (OTCMKTS:RSLSD) and CapsoVision (NASDAQ:CV) - Defense World
CapsoVision, Inc.'s Quiet Period Set To Expire on August 11th (NASDAQ:CV) - MarketBeat
CapsoVision, Inc.’s (NASDAQ:CV) Quiet Period Will End on August 11th - Defense World
Is capsovision scam - AInvest
Roth Capital Predicts CapsoVision's Q2 Earnings (NASDAQ:CV) - MarketBeat
CapsoVision (NASDAQ:CV) Raised to Strong-Buy at Roth Capital - MarketBeat
Understanding the risks associated with CapsoVision's stock - AInvest
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewswire
Capsovision, Inc. shares fall 2.19% intraday as Kioxia Corporation announces new UFS 4.1 devices for automotive applications. - AInvest
Q2 Earnings Estimate for CapsoVision Issued By Roth Capital - Defense World
Roth Capital Upgrades CapsoVision (NASDAQ:CV) to Strong-Buy - Defense World
Capsovision Inc Azioni (CV) Dati Finanziari
Non sono disponibili dati finanziari per Capsovision Inc (CV). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):